MedTrace Logo

Multicentre Validation of How Vascular Biomarkers From Tumor Can Predict the Survival of the Patient With Glioblastoma

NCT03439332 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 305

Last updated 2025-07-08

No results posted yet for this study

Summary

Despite an aggressive therapeutic approach, the prognosis for most patients with glioblastoma (GBM) remains poor. The relationship between non-invasive Magnetic Resonance Imaging (MRI) biomarkers at preoperative, postradiotherapy and follow-up stages, and the survival time in GBM patients will be useful to plan an optimal strategy for the management of the disease.

The Hemodynamic Multiparametric Tissue Signature (HTS) biomarker provides an automated unsupervised method to describe the heterogeneity of the enhancing tumor and edema areas in terms of the angiogenic process located at these regions. This allows to automatically draw 4 reproducible habitats that describe the tumor vascular heterogeneity:

* The High Angiogenic enhancing Tumor (HAT)
* The Less Angiogenic enhancing Tumor (LAT)
* The potentially tumor Infiltrated Peripheral Edema (IPE)
* The Vasogenic Peripheral Edema (VPE)

The conceptual hypothesis is that there is a significant correlation between the perfusion biomarkers located at several HTS habitats and the patient's overall survival.

The primary purpose of this clinical study is to determine if preoperative vascular heterogeneity of glioblastoma is predictive of overall survival of patients undergoing standard-of-care treatment by using the HTS biomarker.

Conditions

Sponsors & Collaborators

  • University of Liege

    collaborator OTHER

  • Hospital de Manises

    collaborator OTHER

  • Hospital de la Ribera

    collaborator OTHER

  • Hospital Vall d'Hebron

    collaborator OTHER

  • Hospital Clinic of Barcelona

    collaborator OTHER

  • Azienda Ospedaliero-Universitaria di Parma

    collaborator OTHER

  • Oslo University Hospital

    collaborator OTHER

  • Juan M Garcia-Gomez

    lead OTHER

Principal Investigators

  • Juan M Garcia Gomez, PhD · Universitat Politècnica de València

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-07
Primary Completion
2018-07-01
Completion
2019-03-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03439332 on ClinicalTrials.gov